Table 2.
The subgroup analysis for OS in patients with HCC
| Subgroup | Number of studies | Pooled OS | Heterogeneity | |||
|---|---|---|---|---|---|---|
| HR[95% CI] | p | I2 | p | |||
| Region | Asia | 5 | 0.65[0.56, 0.76] | < 0.00001 | 0% | 0.53 |
| Non-Asia | 4 | 0.85[0.73, 0.98] | 0.02 | 43% | 0.15 | |
| AFP Lever | AFP < 400 ng/ml | 4 | 0.75[0.65, 0.88] | 0.0003 | 72% | 0.01 |
| AFP ≥ 400 ng/ml | 4 | 0.64[0.54, 0.77] | < 0.00001 | 0% | 0.95 | |
| MVI or EHS | presence | 5 | 0.67[0.59, 0.77] | < 0.00001 | 37% | 0.17 |
| absence | 5 | 0.78[0.65, 0.92] | 0.003 | 68% | 0.01 | |
| BCLC Stage | BCLC B | 4 | 0.64[0.52, 0.79] | < 0.00001 | 45% | 0.14 |
| BCLC C | 4 | 0.70[0.61, 0.79] | < 0.00001 | 63% | 0.04 | |
| Etiology | Hepatitis B | 5 | 0.64[0.55, 0.74] | < 0.00001 | 0% | 0.49 |
| Hepatitis C | 4 | 0.81[0.64, 1.04] | 0.1 | 58% | 0.07 | |
| Non-viral | 4 | 0.91[0.75, 1.11] | 0.37 | 0% | 0.52 | |